Which drugs are typically used for post-exposure prophylaxis (PEP) treatment?

Post-exposure prophylaxis (PEP) is a critical intervention for individuals who may have been exposed to HIV. The correct option involves Truvada and Descovy, which are both antiretroviral medications commonly used in PEP.

Truvada is a combination of tenofovir disoproxil fumarate and emtricitabine, while Descovy combines tenofovir alafenamide and emtricitabine. These drugs are effective in reducing the risk of HIV infection when taken within 72 hours after potential exposure and continued for 28 days. Their efficacy is well-documented, making them the preferred choice for PEP.

The other drug combinations provided in the options do not align with current PEP guidelines. Apretude, though effective as a pre-exposure prophylaxis (PrEP) option, is not used in the context of PEP. Didanosine and Zidovudine are older medications with potential toxicity and are not recommended for PEP. Lopinavir and Ritonavir are used primarily in treatment regimens for HIV but are not recommended for PEP due to their side effect profiles and the availability of more effective alternatives.